Quest Diagnostics Introduces Testing for Oropouche Virus

Core Insights - Quest Diagnostics has launched a new diagnostic laboratory test for the Oropouche virus, an emerging disease prevalent in South and Central America and the Caribbean [1][2]. Company Developments - The new test will be available by prescription for clinical purposes by the end of the month, utilizing polymerase chain reaction (PCR) technology for early-stage diagnosis, with serology testing to follow later this quarter [3]. - Quest Diagnostics was awarded contracts by the U.S. Centers for Disease Control and Prevention (CDC) in September 2024 to support testing and laboratory readiness for emerging infectious diseases, including the Oropouche virus [4]. Industry Context - The Oropouche virus is transmitted by infected biting midges and some mosquito species, with a low current threat level in North America, primarily affecting travelers returning from endemic regions [2]. - The virus can cause severe neuroinvasive diseases such as meningitis and encephalitis, although most individuals recover without intervention [2].